Riya Moodley
YOU?
Author Swipe
View article: P-1424. Patient Experiences at Month 6 after Initiation of Cabotegravir Long-Acting (CAB LA) for PrEP in the First Male Gender Concordant Implementation Science Trial (PILLAR) in the US
P-1424. Patient Experiences at Month 6 after Initiation of Cabotegravir Long-Acting (CAB LA) for PrEP in the First Male Gender Concordant Implementation Science Trial (PILLAR) in the US Open
Background Little is known outside of registrational clinical trials about patient experiences on CAB LA, the first long-acting injectable regimen for HIV prevention. We report real-world experiences and outcomes of men at month 6 (M6) aft…
View article: Efficacy and safety of switching to dolutegravir/lamivudine in virologically suppressed people with HIV-1 aged ≥ 50 years: week 48 pooled results from the TANGO and SALSA studies
Efficacy and safety of switching to dolutegravir/lamivudine in virologically suppressed people with HIV-1 aged ≥ 50 years: week 48 pooled results from the TANGO and SALSA studies Open
Background As the population of people with HIV ages, concerns over managing age-related comorbidities, polypharmacy, immune recovery, and drug-drug interactions while maintaining viral suppression have arisen. We present pooled TANGO and …
View article: Durable Efficacy of Switching From a 3- or 4-Drug Tenofovir Alafenamide–Based Regimen to the 2-Drug Regimen Dolutegravir/Lamivudine in the TANGO Study Through Week 196
Durable Efficacy of Switching From a 3- or 4-Drug Tenofovir Alafenamide–Based Regimen to the 2-Drug Regimen Dolutegravir/Lamivudine in the TANGO Study Through Week 196 Open
Background: Switching to the 2-drug regimen dolutegravir (DTG)/lamivudine (3TC) demonstrated durable noninferior efficacy vs continuing 3- or 4-drug tenofovir alafenamide–based regimens for maintaining virologic suppression in people with …
View article: Very-Low-Level Viremia, Inflammatory Biomarkers, and Associated Baseline Variables: Three-Year Results of the Randomized TANGO Study
Very-Low-Level Viremia, Inflammatory Biomarkers, and Associated Baseline Variables: Three-Year Results of the Randomized TANGO Study Open
Background We compared proportions of participants with target detected, target not detected (TND), and elevated viral load (VL) and assessed baseline variables associated with week 144 inflammatory biomarker levels between dolutegravir-la…
View article: 1559. Healthcare Staff Perceptions of Feasibility and Acceptability on Implementing Injectable HIV Pre-exposure Prophylaxis into Standard of Care: Baseline Results from the PrEP Implementation Study for Cabotegravir Long Acting for Men in the Real World (PILLAR)
1559. Healthcare Staff Perceptions of Feasibility and Acceptability on Implementing Injectable HIV Pre-exposure Prophylaxis into Standard of Care: Baseline Results from the PrEP Implementation Study for Cabotegravir Long Acting for Men in the Real World (PILLAR) Open
Background PILLAR evaluates the feasibility and acceptability of implementation strategies for delivering long-acting Cabotegravir for PrEP (CAB LA) to men who have sex with men and transgender men in low and high-volume PrEP Sites across …
View article: Cardiometabolic Parameters 3 Years After Switch to Dolutegravir/Lamivudine vs Maintenance of Tenofovir Alafenamide–Based Regimens
Cardiometabolic Parameters 3 Years After Switch to Dolutegravir/Lamivudine vs Maintenance of Tenofovir Alafenamide–Based Regimens Open
Background Cardiometabolic outcomes were investigated 3 years after switching to the 2-drug regimen dolutegravir/lamivudine (DTG/3TC) vs continuing 3-/4-drug tenofovir alafenamide (TAF)–based regimens in a multicenter phase 3 noninferiorit…
View article: Assessing the Virologic Impact of Archived Resistance in the Dolutegravir/Lamivudine 2-Drug Regimen HIV-1 Switch Study TANGO through Week 144
Assessing the Virologic Impact of Archived Resistance in the Dolutegravir/Lamivudine 2-Drug Regimen HIV-1 Switch Study TANGO through Week 144 Open
The TANGO study (ClinicalTrials.gov, NCT03446573) demonstrated that switching to dolutegravir/lamivudine (DTG/3TC) was non-inferior to continuing tenofovir alafenamide-based regimens (TBR) through week 144. Retrospective baseline proviral …
View article: Compassionate use of <scp>long‐acting</scp> cabotegravir plus rilpivirine for people living with <scp>HIV</scp>‐1 in need of parenteral antiretroviral therapy
Compassionate use of <span>long‐acting</span> cabotegravir plus rilpivirine for people living with <span>HIV</span>‐1 in need of parenteral antiretroviral therapy Open
Objectives Physicians could request compassionate use of oral and long‐acting (LA) cabotegravir + rilpivirine for people living with HIV‐1 under a single‐patient request programme supported by ViiV Healthcare and Janssen. Outcomes are repo…